Introduction {#section1-1073274820922559}
============

Gastric cancer (GC) is responsible for over 1 000 000 new cases in 2018 and an estimated 783 000 deaths, making it the fifth most frequently diagnosed cancer and the third leading cause of cancer deaths worldwide.^[@bibr1-1073274820922559]^ The incidence rates of GC are markedly elevated in Eastern Asia, including China, Mongolia, Japan, and the Republic of Korea.^[@bibr2-1073274820922559]^ In China, GC has become the second leading cause of cancer deaths in men and women with 679 100 estimated new cases diagnosed each year, and its 5-year survival rate is low because more than 80% of patients are diagnosed at an advanced stage.^[@bibr3-1073274820922559]^

Long-standing screening program and effective early detection method are the most effective strategies to reduce the incidence and mortality of GC. Only 2 countries globally, Japan and Korea, are conducting population-based GC screening.^[@bibr4-1073274820922559]^ In Japan, X-ray photofluorography is the regular screening method, but high cost and fear for radiation exposure have led to a low uptake rate.^[@bibr2-1073274820922559]^ Since endoscopy can detect the early stages of GC, its introduction into communities for GC screening had been highly anticipated, but in reality, its invasiveness has resulted in low acceptance rate.^[@bibr4-1073274820922559]^ Serum tumor marker tests are simple and noninvasive approaches for screening tumors.^[@bibr5-1073274820922559]^ However, the low sensitivity of these markers made the tests for them hardly a primary strategy for early GC detection.^[@bibr6-1073274820922559]^

WNT proteins are secreted signaling factors with multiple functions in development and tumorigenesis.^[@bibr7-1073274820922559]^ Secreted frizzled-related proteins (*SFRPs*), a family of 5 secreted glycoproteins, are identified as possible negative modulators of the WNT signal transduction pathway.^[@bibr8-1073274820922559]^ Encoding one of these proteins, *SFRP2* gene plays an important role in cell growth, apoptosis, and regulation of cell differentiation, and it is often methylated in human cancers.^[@bibr9-1073274820922559]^ Several reports found *SFRP2* to be hypermethylated in GC tissues and blood samples,^[@bibr10-1073274820922559],[@bibr11-1073274820922559]^ suggesting that methylated *SFRP2* may serve as a noninvasive biomarker for early detection of GC. In this study, we evaluated the performance of a plasma methylated *SFRP2* test for the feasibility as a noninvasive screening tool for GC.

Materials and Methods {#section2-1073274820922559}
=====================

Sample Collection {#section3-1073274820922559}
-----------------

Fresh frozen GC tissues (n = 9) and paired adjacent paracancerous tissues (n = 9) were collected at the time of surgery at the Affiliated Hospital of Xuzhou Medical University. All tissue samples were stored at −80°C until use. Plasma specimens were collected from 92 patients with GC, 16 patients with gastric intestinal metaplasia (IM), 26 patients with gastric fundic gland polyp (GFGP), 13 small adenoma (AP, adenomas \<1 cm and without dysplasia or villous component) patients, and 39 patients with hyperplastic polyp (HP), and the diagnoses of all patients were histologically confirmed by a pathologist. Control plasma specimens were collected from 50 patients with no evidence diseases or with chronic superficial gastritis as verified by gastroscopy at the Affiliated Hospital of Xuzhou Medical University ([Table 1](#table1-1073274820922559){ref-type="table"}), and colonoscopy was performed on control patients and confirmed no colonic lesions. Ten-milliliter blood was drawn from each patient and stored at 4°C within 6 hours. The plasma fractions were then separated and immediately frozen at −80°C until use. The blood leukocytes of 4 CRC patients, 2 AP patients, and 15 control patients were collected post plasma separation and frozen at −80°C until use. This study was approved by the Institutional Review Board of the Affiliated Hospital of Xuzhou Medical University (ethics committee reference number: XYFY2019-KL121), and informed consent was obtained from all participating patients and control patients.

###### 

Characteristics of Individuals Enrolled in this Study.

![](10.1177_1073274820922559-table1)

             Number (N)   Gender       Age                  
  ---------- ------------ ------------ ------------ ------- ------
  Total GC   92           67 (72.8%)   25 (27.2%)   31-83   60.7
   I         24           18 (75.0%)   6 (25.0%)    36-75   56.3
   II        18           16 (88.9%)   2 (11.1%)    44-78   61.3
   III       22           12 (54.5%)   10 (45.5%)   42-78   60.7
   IV        8            4 (50.0%)    4 (50.0%)    31-74   59.1
   Unknown   20           17 (85.0%)   3 (15.0%)    47-83   66.2
  IM         16           8 (50.0%)    8 (50.0%)    47-77   61.3
  GFGP       26           8 (30.8%)    18 (69.2%)   20-75   51.3
  AP         13           9 (69.2%)    4 (30.8%)    51-77   63.9
  HP         39           10 (25.6%)   29 (74.4%)   32-88   56.0
  Control    50           31 (62.0%)   19 (38.0%)   22-76   35.1

Abbreviations: AP, adenoma patients; GC, gastric cancer; GFGP, gastric fundic gland polyp; HP, hyperplastic polyp; IM, intestinal metaplasia.

DNA Extraction, Bisulfite Treatment, and Quantitative Real-Time PCR {#section4-1073274820922559}
-------------------------------------------------------------------

Tissue genomic DNA was isolated using DNeasy Blood & Tissue Kit (Qiagen, Hilden, Germany). Leukocyte genomic DNA was isolated using VersaPrep DNA extraction kit (Suzhou VersaBio Technologies Co Ltd, Kunshan, China). Plasma DNA was extracted using a circulating free DNA extraction kit (Suzhou VersaBio Technologies Co Ltd) from 3.5-mL plasma and eluted in 100-µL elution buffer. Subsequently, 100-µL purified cfDNA and genomic DNA isolated from tissue or leukocytes were used for bisulfite conversion and the converted DNA was purified and then eluted in 100 µL of elution buffer. DNA bisulfite conversion and purification of the converted product was performed with a bisulfite conversion kit (Suzhou VersaBio Technologies Co Ltd). All the kits were used according to the manufacturer's instructions.

Purified DNA obtained from the above steps was tested by a methylated *SFRP2* test (Suzhou VersaBio Technologies Co Ltd). Methylated *SFRP2* and an internal control (*ACTB*) can be detected simultaneously in the same multiplex qPCR reaction. Three qPCR replicates were performed for each plasma sample, and a single qPCR reaction was performed for each tissue sample. The total qPCR volume was 30 µL with 15-µL DNA and 15-µL PCR master mix. Real-time PCR was performed on LC480-II thermal cycler (Roche Diagnostics, Mannheim, Germany) using the following cycling conditions: activation at 95°C for 30 minutes, 50 cycles of 95°C for 10 seconds, 58°C for 30 seconds, 72°C for 10 seconds, and final cooling to 40°C for 30 seconds.

Serum Tumor Marker Detection {#section5-1073274820922559}
----------------------------

Serum CEA, CA72-4, and CA19-9 levels were measured by using Roche Cobas 8000 electrochemiluminescence instrument and CA242 was test by using Snibe Diagnostic MAGLUMI 4000 instrument at Department of Laboratory Medicine of the Affiliated Hospital of Xuzhou Medical University. The normal reference values were as follows: CEA ≤ 5 ng/mL, CA72-4 ≤ 6.9 U/mL, CA19-9 ≤ 35 U/mL, CA242 ≤ 20 IU/mL.

Data Analysis {#section6-1073274820922559}
-------------

ΔCp was used to determine the methylation level of *SFRP2* in GC tissues, paired adjacent paracancerous tissues, and leukocytes. ΔCp was defined as the difference between the Cp values for the target (*SFRP2*) and the internal control gene (*ACTB*). The results for plasma specimens were considered "invalid" if *ACTB* Cp (output data from Roche LC480II real-time PCR machine defines threshold cycle number as Cp) was greater than 35.0, and methylated *SFRP2* was considered "detected" if its Cp value was less than 39.0. Methylated *SFRP2* was analyzed with a 2/3 rule in which a plasma sample was scored positive if at least 2 of 3 PCR replicates had valid amplification curves (2/3 algorithm). Data were subjected to statistical analysis by IBM SPSS software for Windows version 22.0, and *t* test was used for comparison of 2 samples at the significant level of *P* \< .05. Sensitivity and specificity data were used to plot the receiver operating characteristic (ROC) curve. The mean Cp values of IM, GFGP, AP, HP, GC, and control patients for methylated *SFRP2* were used to represent methylation level. Because most control patients were not detected in qPCR reaction, their Cp values were set to 50 (the maximal number of PCR cycles) to plot ROC curve and the chart for methylation levels.^[@bibr12-1073274820922559]^ The Youden index was used to evaluate the effectiveness of plasma methylated *SFRP2* in detecting IM and patients with GC,^[@bibr13-1073274820922559]^ it was thus calculated by the following equation:
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Results {#section7-1073274820922559}
=======

Measured by a methylated *SFRP2* test, *SFRP2* methylation levels were higher in 88.9% (8 of 9) of GC tissues than in their paired adjacent paracancerous tissues (*P* \< .05, [Figure 1A](#fig1-1073274820922559){ref-type="fig"}). In addition, *SFRP2* methylation levels in the leukocytes of patients with GC, AP patients, and normal patients seemed no significant difference (*P* \> .05, [Figure 1B](#fig1-1073274820922559){ref-type="fig"}), thus making plasma methylated *SFRP2* test a candidate for distinguishing GC and normal patients. To evaluate the feasibility of methylated *SFRP2* test for early GC detection, 236 plasma samples were collected from patients of the Affiliated Hospital of Xuzhou Medical University, of which 92 were from patients with GC, 16 from IM patients, 26 from GFGP patients, 13 from AP patients, 39 from HP patients, and 50 from control patients. The patients with GC ranged from 31 to 83 years old with a mean age of 60.7, and 72.8% were male patients. The control patients ranged from 22 to 76 years old with a mean age of 35.1, and 62.0% were males ([Table 1](#table1-1073274820922559){ref-type="table"}).

![Methylated *SFRP2* level in GC tissues, paired adjacent paracancerous tissues (A) and leukocytes (B). GC, gastric cancer.](10.1177_1073274820922559-fig1){#fig1-1073274820922559}

Of 92 GC plasma samples whose stages were determined based on the surgically resected specimens, methylated *SFRP2* was detected in 50.0% of stage I (12 of 24), 55.6% of stage II (10 of 18), 59.1% of stage III (13 of 22), 87.5% of stage IV (7 of 8), and 70.0% of unknown stage (14 of 20) samples ([Figure 2A](#fig2-1073274820922559){ref-type="fig"}). The sensitivity for detecting all stage GC by methylated *SFRP2* test was 60.9% (95% confidence interval \[CI\]: 50.1%-70.7%) with a specificity of 86.0% (95% CI: 72.6%-93.7%). In addition, methylated *SFRP2* test also demonstrated significantly higher positive detection rates for GC and IM patients than control patients (*P* \< .05), whereas the positive detection rates for GC and IM patients showed no significant difference (*P* = .786; [Figure 2B](#fig2-1073274820922559){ref-type="fig"}). Furthermore, the positive detection rate for patients with GC was also significantly higher than benign polyps (GFGP, AP, and HP, *P* \< .05). As Cp values of a methylated biomarker reflect its methylation levels, where higher Cp values represent lower methylation levels, the mean Cp values of methylated *SFRP2* for different patient groups were consistent with their disease status ([Figure 2C](#fig2-1073274820922559){ref-type="fig"}). Particularly, the mean Cp values of methylated *SFRP2* showed a decreasing trend across stage I to IV, and the mean Cp values for GC and IM patients were significantly lower than those for GFGP, AP, HP, and control patients, showing a pattern consist with that of positive detection rates shown in [Figure 2A and B](#fig2-1073274820922559){ref-type="fig"}.

![Positive detection rates and methylation levels of methylated *SFRP2* in detecting intestinal metaplasia, GFGP, AP, HP, GC, control, and GC across stages I-IV. A, Sensitivity and specificity of methylated *SFRP2* test in detecting GC. B, The difference of positive detection rates between IM, GFGP, AP, HP, GC, and control patients detected by methylated *SFRP2* test. C, Methylation levels of methylated *SFRP2* in IM, GFGP, AP, HP, GC, and control patients. AP indicates adenoma patients; GC, gastric cancer; GFGP, gastric fundic gland polyp; HP, hyperplastic polyp; IM, intestinal metaplasia.](10.1177_1073274820922559-fig2){#fig2-1073274820922559}

The ROC curve for plasma methylated *SFRP2* test detecting GC is shown in [Figure 3](#fig3-1073274820922559){ref-type="fig"}. The area under the curve for GC detection was 0.784 (95% CI: 0.709-0.859). The Youden index of plasma methylated *SFRP2* in detecting IM and patients with GC were 42.3% and 46.9%, respectively. Furthermore, there was no significant difference among the positive detection rates of methylated *SFRP2* test in detecting GC between different ages, genders, tumor locations, tumor sizes, or tumor differentiation statuses (*P* \> .05, [Table 2](#table2-1073274820922559){ref-type="table"}). Overall, the above results demonstrated higher sensitivity of methylated *SFRP2* in detecting patients with GC and IM than benign polyp patients and normal patients.

![Receiver operating characteristic curve for methylated *SFRP2* test in detecting gastric cancer. AUC = 0.784 (95% CI: 0.709-0.859). AUC indicates area under the curve; CI, confidence interval.](10.1177_1073274820922559-fig3){#fig3-1073274820922559}

###### 

Results of Methylated *SFRP2* Test in Detecting GC Between Different Ages, Genders, Tumor Locations, Tumor Sizes, and Tumor Differentiation Statuses.

![](10.1177_1073274820922559-table2)

                                                        Methylated *SFRP2* (%)   *P* Value
  ----------------------------------------------------- ------------------------ -----------
  Age                                                                            
   ≤60 (n = 44)                                         50.0%                    .055
   \>60 (n = 48)                                        70.8%                    
  Gender                                                                         
   Male (n = 67)                                        59.7%                    .812
   Female (n = 25)                                      64.0%                    
  Location                                                                       .315^a^
   Cardia (n = 20)                                      60.0%                    .431^b^
   Gastric body (n = 15)                                40.0%                    1.000^c^
   Gastric angle (n = 9)                                77.8%                    .105^d^
   Gastric antrum (n = 20)                              60.0%                    .315^e^
   NA (n = 28)                                          67.9%                    .431^f^
  Size                                                                           
   \<3 cm (n = 20)                                      50.0%                    1.000^g^
   3-6 cm (n = 24)                                      50.0%                    .176^h^
   \>6 cm (n = 16)                                      75.0%                    .188^i^
   NA (n = 32)                                          68.8%                    
  Differentiation status                                                         
   Poorly (n = 29)                                      62.1%                    .795^j^
   Moderately differentiated (n = 32)                   56.3%                    .552^k^
   Between well and moderately differentiated (n = 3)   33.3%                    .582^l^
   NA (n = 28)                                          67.9%                    

Abbreviations: GC, gastric cancer; NA, not applicable.

^a^ *P* value between cardia and gastric body.

^b^ *P* value between cardia and gastric angle.

^c^ *P* value between cardia and gastric antrum.

^d^ *P* value between gastric body and gastric angle.

^e^ *P* value between gastric body and gastric antrum.

^f^ *P* value between gastric angle and gastric antrum.

^g^ *P* value between \<3 cm and 3-6 cm.

^h^ *P* value between 3-6 cm and \>6 cm.

^i^ *P* value between \<3 cm and \>6 cm.

^j^ *P* value between poorly differentiated and moderately differentiated.

^k^ *P* value between moderately differentiated and well differentiated.

^l^ *P* value between poorly differentiated and well differentiated.

Among the 92 patients with GC, serum CEA, CA72-4, CA19-9, and CA242 levels were measured in 79 patients. For these patients, the positive detection rates for GC detection by methylated *SFRP2* test and 4 serum tumor markers were showed in [Figure 4](#fig4-1073274820922559){ref-type="fig"}. While methylated *SFRP2* test detected 55.0% stage I and 50.0% stage II GC, CEA, and CA72-4 had lower positive detection rates in stage I-II GC, and CA19-9 and CA242 missed all of stage I-II GC completely. The positive detection rates for serum CEA, CA72-4, CA19-9, and CA242 detecting all stage GC were 22.8%, 16.5%, 12.7%, and 11.4%, respectively. In contrast, methylated *SFRP2* test had a 58.2% positive detection rate in detecting all stage GC. The positive detection rate for serum tumor markers was improved with the combined use of all 4 (35.4%) markers, which, however, was still significantly lower than that of methylated *SFRP2* test. And combination of methylated *SFRP2* and 4 serum tumor markers achieved a 68.4% positive detection rate, significantly higher than that of the combination of 4 serum tumor markers only.

![The positive detection rates of serum CEA, CA72-4, CA19-9, CA242, and plasma methylated *SFRP2* test for detecting GC. GC indicates gastric cancer.](10.1177_1073274820922559-fig4){#fig4-1073274820922559}

Discussion {#section8-1073274820922559}
==========

Gastric cancer is one of the most common malignancies worldwide, and several new methods for early GC detection have been published in recent years.^[@bibr14-1073274820922559],[@bibr15-1073274820922559]^ DNA methylation plays a significant role in gastric carcinogenesis.^[@bibr16-1073274820922559]^ Therefore, using DNA methylation in serum or plasma as a molecular biomarker may be an alternative strategy for GC early detection and screening.

Aberrant hypermethylation of WNT antagonist genes is associated with the development of GC,^[@bibr17-1073274820922559]^ and *SFRP2*, one of these genes, has been published in several studies. Nojima et al observed methylated *SFRP2* in 95.6% (44 of 46) GC tissues.^[@bibr17-1073274820922559]^ Zhang et al found a significantly higher frequency of *SFRP2* methylation in the plasma DNA of patients with GC than that of controls (71.9% vs 42.9%).^[@bibr11-1073274820922559]^ Cheng et al showed that *SFRP2* was significantly downregulated in GC as compared to adjacent paracancerous tissues (*P* \< .01), and methylated *SFRP2* was detected in 73.3% (22 of 30) GC tissues, 20% (6 of 30) adjacent paracancerous tissues, and 66.7% (12 of 18) serum samples from patients with GC but 0.0% (0 of 18) in controls.^[@bibr10-1073274820922559]^

In this study, we demonstrated that plasma methylated *SFRP2* test had 60.9% sensitivity and 86.0% specificity for GC detection, similar to the results from earlier studies.^[@bibr10-1073274820922559],[@bibr17-1073274820922559]^ Compared to those studies, more patients with GC were enrolled, and methylated *SFRP2* was analyzed for different age and gender groups, different tumor locations, sizes, stages, and differentiation statuses. Therefore, our study presented a more comprehensive evaluation of methylated *SFRP2* levels in the blood samples of patients with GC. Meanwhile, the results of this study showed that methylated *SFRP2* test detected 56.3% gastric IM, a significantly higher positive detection rate than that for control patients ([Figure 2B](#fig2-1073274820922559){ref-type="fig"}, *P* = .001), but the positive detection rates of plasma methylated *SFRP2* for GC and IM patients showed no significant difference ([Figure 2B](#fig2-1073274820922559){ref-type="fig"}). These results might be due to the smaller sample size of IM samples than that of patients with GC (16 vs 92). Moreover, most patients with GC with clear TNM stages were early stage GC (58.3%), which could also account for similar positive detection rates between IM and GC groups. Furthermore, gastric IM is a relatively frequent precancerous lesion^[@bibr18-1073274820922559]^ so that screening and intervention for gastric IM has been considered as a primary strategy for prevention and early screening of GC.^[@bibr19-1073274820922559]^ Taken together, our results suggested that methylated *SFRP2* may also be a viable biomarker for detecting early stage GC and precursor lesions.

Serum tumor marker test has become a common method for screening GC. He et al reported the results of combining serum AFP, CEA, CA125, and CA19-9 to improve the sensitivity for GC diagnosis. Whereas the sensitivities of AFP, CEA, CA125, and CA19-9 individually for the detection of GC ranged from 4.7% to 20.8%, the combined test showed a sensitivity of 40.3%.^[@bibr20-1073274820922559]^ Reported in another study, the sensitivities of CA72-4, CEA, CA125, and CA19-9 for early GC detection were 33.0%, 25.5%, 31.1%, and 38.7%, respectively, but when used in combination, the 4 markers showed an increased sensitivity of 66.0%.^[@bibr21-1073274820922559]^ In this study, we compared the sensitivities of serum CEA, CA72-4, CA19-9, and CA242 to that of plasma methylated *SFRP2* for GC detection. While the sensitivities of CEA, CA72-4, CA19-9, and CA242 were 22.8%, 16.5%, 12.7%, and 11.4%, the combination of all 4 markers improved the sensitivity to 35.4%. In contrast, methylated *SFRP2* alone demonstrated a significantly higher sensitivity of 58.2%. The data from this study and previous studies indicated that plasma methylated *SFRP2* had significantly higher sensitivity for GC detection than any serum tumor marker alone. Therefore, plasma methylated *SFRP2* could be a more sensitive biomarker for early GC detection. Moreover, the combination of serum tumor markers with plasma methylated *SFRP2* could achieve even higher sensitivity, suggesting the possible application of this combination in clinics for early GC detection as well as the assessment for the therapeutic effects of different treatments and the prognosis of patients with GC.

However, there are several limitations in this study. For example, the lack of the comparison between plasma methylated *SFRP2* and serum tumor markers in normal patients. Meanwhile, the number of patients enrolled in this study was relatively low, especially when patients were further divided into IM, GFGP, AP, HP groups as well as different stages of patients with GC. Further increasing the number of patients of each group will make it possible to distinguish the diagnostic performance of plasma methylated *SFRP2* assay for these diseases. Moreover, we could collect more specimens from multiple clinical centers and combined plasma methylated *SFRP2* with other biomarkers, such as serum PGI concentration and the PGI/II ratio, to evaluate and enhance its sensitivity in detecting early stage GC in the further studies.

Conclusion {#section9-1073274820922559}
==========

We evaluated the feasibility of using methylated *SFRP2* test for the early detection of GC and precursor lesions. Its sensitivities for GC and gastric IM were 60.9% and 56.3% with a specificity of 86.0%. The results thus indicated that plasma methylated *SFRP2* test may be a valuable tool for the noninvasive detection of GC and precursor lesions.
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